1-4 of 4
Elizabeth L. Lockerman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

Free
Kyung-A Song, Matthew J. Niederst, Timothy L. Lochmann, Aaron N. Hata, Hidenori Kitai, Jungoh Ham, Konstantinos V. Floros, Mark A. Hicks, Haichuan Hu, Hillary E. Mulvey, Yotam Drier, Daniel A.R. Heisey, Mark T. Hughes, Neha U. Patel, Elizabeth L. Lockerman, Angel Garcia, Shawn Gillepsie, Hannah L. Archibald, Maria Gomez-Caraballo, Tara J. Nulton, Brad E. Windle, Zofia Piotrowska, Sinem E. Sahingur, Shirley M. Taylor, Mikhail Dozmorov, Lecia V. Sequist, Bradley Bernstein, Hiromichi Ebi, Jeffrey A. Engelman, Anthony C. Faber
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (1): 197–208.
https://doi.org/10.1158/1078-0432.CCR-17-1577
Published: 02 January 2018
View articletitled, Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
Open the PDF for Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM in another window
Includes: Supplementary data
Journal Articles

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Free
Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey, Elizabeth L. Lockerman, Angel R. Garcia, Zofia Piotrowska, Lecia V. Sequist, Jeffrey A. Engelman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (17): 3924–3933.
https://doi.org/10.1158/1078-0432.CCR-15-0560
Published: 31 August 2015
View articletitled, The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Open the PDF for The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies in another window
Includes: Supplementary data
Journal Articles

Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer

Free
Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L. Lockerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelman, Naoya Fujita
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 166–174.
https://doi.org/10.1158/1078-0432.CCR-14-1385
Published: 05 January 2015
View articletitled, Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Open the PDF for Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer in another window
Includes: Supplementary data
Journal Articles

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

Free
Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5686–5696.
https://doi.org/10.1158/1078-0432.CCR-14-1511
Published: 13 November 2014
View articletitled, Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Open the PDF for Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib in another window
Includes: Supplementary data